Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That’s not going to work here. May want to check out the SEC filings. Company has been CFP for a while now. Would love to see shorts get burned.
Who doesn’t like a crazy dog barking during a conference call?
I think we’re still at least a few years out from acquisition. We have too much going on near term. Nasrat has also hinted at another drug family about a year ago that we haven’t heard anything about yet (cardio related?). Would be interesting to see if he resurrects SequestOx v2.0 mid-term knowing opioid scripts will likely return. Buyback program to be implemented with R&D/excess cash split, upgrading to NASDAQ, etc. If all goes well with current irons in the fire, we are sitting pretty. Not sure how big Burel is going to be, but had huge volume previously as auth generic. We are not the auth generic, but I’m cautiously optimistic that this will be a solid way to get decent traction with XR that has eluded us so far despite the significant market size.
Positive Vyvanse BE study wasn’t enough followed by FDA submission or deal with Prasco Burel that starts 1/1 for Adderall XR or how about Generic Oxy filing accepted by FDA?
I think you mean Vigabatrin launch. It’s already approved. Pyros has been prepping for launch for months.
Would be nice to see this in likely chrono order. Got some nice things coming up, no pun intended re goathumpers.
Thx for confirming. Didn’t reference filing.
I believe 1.3B is total approved share count, not issued and outstanding.
Nice article and reinforces push to build safety net with critical medicines. We did get a loan in the past that we didn’t have to pay back. That was the PPA loan during Covid that was forgiven.
Share price and acquisitions are based in financial formulas, guardrails and future potential within reason. Investors need to learn those basics. It’s not twisting. It’s finance 101 basics.
I would love to see the math behind 2% of a $10B market (inaccurate market size when Vyvanse is approved anyways). Y guess is that you are basing a huge PE on gross rev, not profit. Don’t forget cost structure and reasonable PE for generic industry.
So what you are a saying is that in our current $2B market being at a dime, with a $5B market we will be at a quarter. Vyvanse wont be a $5B market when we enter. That market will soon be shrinking by the day and will shrink significantly further once all the generics hit after 180-day stay is completed.
Adderalls are close to $2B market by themselves. Adderall IR has done well, XR on the other hand…
Market size isn’t everything, but it is important when factoring market capture and penetration.
12B market cap? That’s not even in the ballpark of reality.
I believe it shot up to 0.97 over a very short time frame.
Going to break a dime today and keep inching up?
NDA margins vs ANDA margins. Much different market and story. Company is now consistently profitable, but forward PE is much smaller in generic world.
It will not be a $5B market when Vyvanse is approved and it will be an even smaller market when they launch. Keep an eye on it and you’ll see.
You forgot the decimal.
Applesauce is all I have to say…
Elite won’t be able to get much more quota for XR, per Nasrat’s words. Prasco/Burel on the other hand…
First SequestOx wasn’t a great product, the CEO knew it and had to submit a 2.0 version. Had FDA gone route of forcing non-ADT off the market, which is where they were leaning, Elite would have been the leader among the opioid space on getting a significant market share vs 5-10%.
Please note that Adderall ER has a total market of like $1.5B and yet where do Elite’s Adderall XR sales sit today? Less than 1% of the total market. Burel is going to open doors here, but Elite barely scratched the surface. Let’s be cognizant of total market capture as total market means nothing if you can’t sell your way out of a paper bag (Lannett).
It will be under Burel label. No longer authorized generic.
He talked about it last cc. FDA asked for companies to give up their unused quota. No company is going to do that.
Because SequestOx failed. We are a completely different company, plus, he wants to sell out at some point. This is in his best interest.
Would love to see more quota from DEA.
Years ago Nasrat said he would hit up investor conferences back when SequestOx was on verge of FDA decision. Since that never occurred, Elite became a generic company and it took time to pivot. If Elite does actually pursue an exchange upgrade, there is nothing better than to start getting your name out there to educate investors and creating a pipeline. Looking forward to 2024 financial results as he redirected talk of a stock repurchase program that he has ignored for years. Let’s see when financials will dictate that will be feasible.
I’m sorry. Please don’t believe everything you read.
https://valuewiki.wordpress.com/2007/04/26/the-myth-of-the-paid-basher/
This has more insight to that post that keeps getting recycled. Believe what you will.
Doubtful. No one is paid to be a basher, similar to no one is paid to be a pumper.
That’s about the stock price Elite would be at if we only had 13M outstanding shares as well.
I expect Elite to have a buyback program announced and in place within the next 2 years. There is a lot in the pipeline to drive some huge tailwinds for the company, but will require some significant capex investment as well to keep driving future growth. There will be plenty to carve out for initial and ongoing buyback.
Trust, but verify. Thanks Gorby.
Regardless, it’s an upcoming tailwind. Glad they finally are moving forward. I assume REMS held this up for a year.
Lannett was one of original batch that got initial approval.
That is the 10-month mark by which FDA has to respond from Dec 22nd filing. We may not find out for a few business days after that in PR. Expecting another one to add under Elite’s label.
Vyvanse has a ton of generics waiting to go into play after the 180-day first filer expires…several months down the road. We’ll be a little late to the party, but it’s a big market and we should fare well.
What they say is one thing, what they do is completely different.
She does not have a 5-year hold timeframe. She pumps and then sells.
She flips all her stocks, not a long term holder.
We have plenty to go on with what’s being worked on. There might be 1-2 more releases prior to next cc. Eager to see sales momentum this Q. Should be getting close to $10M. If we don’t break it this Q, we certainly will the next. Most tailwinds Elite has ever had.
Had me for a second. Stock is not halted.
Got some sweet news coming between now and end of year to tee up next fiscal year. Good times.